Norges Bank Uni Qure N.V. Transaction History

Norges Bank

$716 Trillion
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $909,168 - $1.12 Million	207,100 New	207,100 $927,000
Q4 2023 Feb 09, 2024	BUY	$5.63 - $8.27 $1.17 Million - $1.71 Million	207,100 New	207,100 $1.4 Million
Q3 2023 Nov 13, 2024	BUY	$6.71 - $11.83 $1.39 Million - $2.45 Million	207,100 New	207,100 $1.39 Million
Q3 2023 Nov 13, 2023	SELL	$6.71 - $11.83 $4.14 Million - $7.31 Million	-617,587 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$11.12 - $22.2 $3.68 Million - $7.35 Million	331,260 Added 159.95%	538,360 $6.17 Million
Q2 2023 Aug 14, 2023	SELL	$11.12 - $22.2 $3.99 Million - $7.96 Million	-358,587 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$18.7 - $23.07 $10.1 Million - $12.4 Million	538,360 New	538,360 $10.8 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $14 Million - $21.1 Million	773,494 New	773,494 $17.5 Million
Q3 2022 Nov 13, 2023	BUY	$16.98 - $25.54 $10.5 Million - $15.8 Million	617,587 New	617,587 $11.6 Million
Q2 2022 Aug 14, 2023	BUY	$13.15 - $20.45 $4.72 Million - $7.33 Million	358,587 New	358,587 $6.68 Million
Q1 2022 May 12, 2023	SELL	$14.54 - $21.5 $6.03 Million - $8.92 Million	-414,907 Reduced 53.64%	358,587 $6.48 Million
Q1 2022 May 09, 2022	SELL	$14.54 - $21.5 $5.98 Million - $8.84 Million	-410,983 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$20.24 - $36.01 $8.32 Million - $14.8 Million	410,983 New	410,983 $8.52 Million
Q3 2021 Nov 14, 2022	BUY	$26.01 - $38.22 $10.3 Million - $15.2 Million	396,947 New	396,947 $12.7 Million
Q3 2021 Nov 05, 2021	SELL	$26.01 - $38.22 $8.03 Million - $11.8 Million	-308,750 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$29.97 - $37.17 $9.25 Million - $11.5 Million	308,750 New	308,750 $9.51 Million
Q2 2021 Aug 10, 2021	SELL	$29.97 - $37.17 $9.56 Million - $11.9 Million	-319,131 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$29.24 - $42.03 $9.33 Million - $13.4 Million	319,131 New	319,131 $10.8 Million
Q1 2021 May 07, 2021	SELL	$29.24 - $42.03 $11.3 Million - $16.2 Million	-386,403 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$35.35 - $50.67 $13.7 Million - $19.6 Million	386,403 New	386,403 $14 Million
Q4 2020 Feb 10, 2021	SELL	$35.35 - $50.67 $13.7 Million - $19.6 Million	-386,403 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$35.98 - $47.66 $13.9 Million - $18.4 Million	386,403 New	386,403 $14.2 Million
Q3 2020 Nov 10, 2020	SELL	$35.98 - $47.66 $13 Million - $17.2 Million	-360,371 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$45.06 - $67.74 $16.2 Million - $24.4 Million	360,371 New	360,371 $16.2 Million
Q2 2020 Aug 07, 2020	SELL	$45.06 - $67.74 $17 Million - $25.6 Million	-378,092 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$40.01 - $73.97 $15.1 Million - $28 Million	378,092 New	378,092 $17.9 Million
Q1 2020 May 08, 2020	SELL	$40.01 - $73.97 $15.1 Million - $28 Million	-378,092 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$37.13 - $74.62 $14 Million - $28.2 Million	378,092 New	378,092 $27.1 Million
Q4 2019 Feb 12, 2020	SELL	$37.13 - $74.62 $7.33 Million - $14.7 Million	-197,395 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$39.36 - $76.8 $7.77 Million - $15.2 Million	197,395 New	197,395 $7.77 Million

Others Institutions Holding QURE

# of Institutions

153

Shares Held

41M

Call Options Held

925K

Put Options Held

617K

Vestal Point Capital, LP New York, NY

4.75M
Shares

$27.1 Million
1.78% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

2.78M
Shares

$15.9 Million
0.81% of portfolio
Boxer Capital, LLC San Diego, CA

2.23M
Shares

$12.7 Million
0.58% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.19M
Shares

$12.5 Million
0.01% of portfolio
Abrdn PLC

1.93M
Shares

$11 Million
0.02% of portfolio

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $266M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account